Nykredit A S Buys New Position in Natera, Inc. $NTRA

Nykredit A S purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 57,455 shares of the medical research company’s stock, valued at approximately $15,596,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NTRA. Aubrey Capital Management Ltd grew its position in Natera by 1.9% in the 2nd quarter. Aubrey Capital Management Ltd now owns 16,000 shares of the medical research company’s stock worth $4,345,000 after purchasing an additional 300 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of Natera during the 2nd quarter worth approximately $617,000. Beaconlight Capital LLC boosted its stake in shares of Natera by 58.7% in the 2nd quarter. Beaconlight Capital LLC now owns 53,312 shares of the medical research company’s stock worth $14,472,000 after buying an additional 19,723 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Natera in the second quarter valued at approximately $1,385,000. Finally, Senator Investment Group LP bought a new position in shares of Natera in the second quarter valued at approximately $8,822,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider John Fesko sold 6,517 shares of Natera stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the sale, the insider owned 197,257 shares in the company, valued at approximately $63,424,043.21. This trade represents a 3.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 15,160 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the transaction, the insider directly owned 110,859 shares of the company’s stock, valued at approximately $36,238,698.51. This represents a 12.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 71,206 shares of company stock worth $19,944,069. 5.05% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently commented on NTRA shares. BTIG Research lifted their price target on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 7th. TD Cowen raised their target price on Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research report on Friday, August 7th. The Goldman Sachs Group assumed coverage on shares of Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 price target for the company. Wells Fargo & Company boosted their price objective on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Stephens increased their target price on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $319.38.

Natera Price Performance

NTRA opened at $328.18 on Friday. The firm has a market capitalization of $47.30 billion, a P/E ratio of -241.31 and a beta of 1.54. Natera, Inc. has a one year low of $157.43 and a one year high of $343.18. The company has a fifty day moving average price of $292.62 and a 200-day moving average price of $237.63.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm’s revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.74) earnings per share. On average, analysts expect that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.